ORIGINAL ARTICLE Postprandial lipemia in diabetic men during hypolipemic therapy
Education Program [NCEP] as fasting cholesterol >200 mg/dl) and 12 patients had hypertriglyceridemia (defined by the NCEP as fasting TG >200 mg/dl). In the AH group 17 patients had hypercholesterolemia and 10 men had hypertriglyceridemia. Subjects with DM received oral hypoglycemic drugs and no insulin. The characteristics of the study groups are presented in TAbLE 1.
According to the guidelines of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes 8 , patients with DM and hypercholesterolemia received statin as a first choice drug (class Ia indication), patients with DM and hypertriglyceridemia received fibrate (Lipanthyl, Solvay) (class IIb indication). Simvastatin (Simvasterol, Polpharma) was administered in a daily dose of 20 mg and fenofibrate in a dose of 267 mg/d. The same therapy was administered in men with hyperlipemia and no DM. No side effects were observed.
All men underwent physical examination. Blood samples were obtained from each participant at baseline, after 6 and after 12 weeks of therapy. In the control group blood samples were drawn once in the fasting state and after a meal.
Blood samples were obtained 12 h after the last meal and 3 h after eating a standard high-fat meal (100 g of fat, 1500 kcal). The fat composition determined by gas chromatography was as follows: 41.4% -oleinic acid, 24.7% -palmitic acid, 16.7% -stearic acid, 8.8% -linoleic acid and 9.4% -other acids.
All patients gave their informed written consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Ethics Committee in Wrocław.
biochemical para meters Total cholesterol, HDL cholesterol (HDL-C) and TG were assayed with the SPINREACT kit (Sant Esteve De Bas, Girona, Spain). LDL cholesterol (LDL-C) levels were measured using Friedewald equation. The QU-ANTOLIP® HDL kit (Technoclone GmbH, Vienna, Austria) was used for precipitation of cholesterol into HDL2 and HDL3 cholesterol subfractions (HDL2-C and HDL3-C).
dyslipidemia it coexists with HDL deficiency, which additionally increases morbidity and mortality rates. 6 High postprandial lipemia, or postprandial dysregulation of meta bolism, is another risk factor inducing oxidative stress, which increases the postprandial rise in glucose and TG levels. These anomalies are observed in poorly controlled diabetes, abdominal obesity, and insulin resistance. 1,2 Hypolipemic therapy in a high risk population, including patients with coronary artery disease, restores normal lipid profile and reduces postprandial lipemia. 7 Postprandial lipemia is usually evaluated as changes of the area under the curve of triglyceridemia, assessed at consecutive hours after a standard meal. Relevant data can also be obtained from the analysis of absolute and relative lipid changes (compared to the fasting value) evaluated at a particular point of time, preferably when changes in TG levels are most pronounced, e.g. 3 h after the meal. The mechanisms of lipid homeostasis after stimulation remain to be elucidated. Associations between maximum fasting and postprandial lipemia values or postprandial changes in inflammatory activity remain unclear.
The aim of the study was to compare lipid and protein alterations induced by a high-fat meal in men with diabetes mellitus (DM) and subjects with normal lipid profile. Since all patients with DM had lipid abnormalities, the second control group comprised men with hyperlipemia and no DM. In addition, the effect of short-term hypolipemic therapy on postprandial lipemia and potential postprandial changes in inflammatory response were investigated.
PATIENTs ANd mEThOds study groups Postprandial lipemia was induced by a standard meal in 113 men: 26 with type 2 DM, 27 with hyperlipemia and no DM (asyptomatic hyperlipemia -AH), and 60 normolipemic subjects. Exclusion criteria were as follows: liver, kidney and thyroid diseases, inflammatory disorders, and malignancy. In the DM group 14 men had hypercholesterolemia (defined by the National Cholesterol Hypolipemic therapy reduced postprandial lipemia induced by a high-fat meal in patients with DM. There was a significantly lower increase in postprandial TG levels already after 6 weeks of treatment (p <0.001). The reduction in lipemia was maintained until the 12th week of the therapy (FIGuRE). Fibrate was more effective (∆TG reduced from 126 ±115 mg/dl to 33 ±56 mg/dl, n = 12, p <0.05) than statin (∆TG reduced from 107.8 ±84 mg/dl to 36 ±61 mg/dl, n = 14, p <0.01).
Changes in lipid meta bolism and inflammatory activity in patients with hyperlipemia and no diabetes After 6 weeks of hypolipemic treatment, mean fasting LDL-C levels were decreased (p <0.05) but the effect was not observed after 12 weeks of the therapy. TG and HDL-C levels did not change significantly. Medications administered during the study did not have a significant effect on glucose, apo A, apo B, and hsCRP levels (TAbLE 3) .
Prior to treatment, postprandial lipemia (∆TG) in patients with AH (76.3 ±80 mg/dl) was insignificantly higher compared to the control group (62.1 ±52.5 mg/dl). Statin or fibrate administration did not have any effect on lipemia induced by a high-fat meal until the 12th week of treatment (FIGuRE).
The reduction in postprandial changes in TG, induced by hypolipemic drugs, was similar in the statin (reduction from 68.3 ±81.6 mg/dl to 42.5 ±35.6 mg/dl, n = 17) and the fibrate groups (reduced from 71.9 ±59.3 mg/dl to 54.6 ±63.2 mg/dl, n = 10).
Correlations between lipid and protein para meters during hypolipemic therapy in the study groups In all men positive linear correlations between fasting apo B and LDL-C levels (r = 0.37, p <0.001), and between apo A and HDL-C levels (r = 0.49, p <0.001) were detected. These associations were observed both in the fasting state and after the meal in separate groups (TAbLE 4) .
A positive correlation between TG and apo B levels in the fasting state and/or postprandially was noted after 6 weeks of hypolipemic therapy in DM patients, and 12 weeks of treatment in AH Levels of apolipoproteins A and B (apo A and B) were determined by immunoturbidimetry with the DADE Behring Marburg GmbH test (Marburg, Germany). High-sensitivity C-reactive protein (hsCRP) levels were measured by immunonephelometry using the CardioPhase hsCRP Dade Behring kit. The results are evaluated by comparison with a standard concentration in N Rheumatology Standard SL against the inter national reference preparation BCR -CRM 470.
statistical analysis Statistical analysis was performed using Statistica PL 6.0 software (Stat Soft, Poland). Mean value and standard deviation (SD) of variables were estimated (the standard error of the mean [SEM] value is presented in the FIGuRE). The Shapiro-Wilk test was used to assess the distribution of variables. In the case of variables with non-normal distribution the Kruskal-Wallis one-way analysis of variance (ANOVA) was used. Differences between mean value of variables were assessed with the post-hoc Newman-Keuls test. Correlations between the study para meters were expressed as correlation coefficient (r) -Pearson's for variables with normal distribution or Spearman's for variables with non-normal distribution. A p <0.05 was considered statistically significant.
REsuLTs Changes in lipid meta bolism and inflamma
tory activity in patients with type 2 diabetes In patients with DM absolute postprandial increase in TG levels (postprandial TG value minus fasting TG value, ∆TG = TG p -TG o ) before the therapy (140 ±68.0 mg/dl) was significantly higher compared to men with hyperlipemia and no DM (76.3 ±80 mg/dl, p <0.05) or to normolipemic controls (62.1 ±52.5 mg/dl, p <0.001).
Statistically significant changes in lipid and glucose levels occurred during the hypolipemic therapy (TAbLE 2) . Statin administration led to a decrease in total cholesterol and LDL levels (after 12 weeks of therapy: 233 ±28 mg/dl to 187 ±37 mg/dl, 143 ±47 mg/dl to 107 ±34 mg/dl, respectively). A 12-week fibrate therapy reduced TG levels (from 280 ±95.8 mg/dl to 224 ±104 mg/dl) and increased HDL-C levels (from 39.0 ±9.1 mg/ dl to 45.6 ±10.9 mg/dl). 
FIGuRE
Changes in plasma triglyceride levels (∆TG) in men with type 2 diabetes (DM, n = 26), patients with hyperlipemia and no DM (asymptomatic hyperlipemia - AH, n = 27) at baseline, after 6 and 12 weeks of hypolipemic therapy, and the control group (C, n = 60). Data are given as mean ± standard error of mean.
Study), and LIPID. 9 Also fibrate has a beneficial effect on lipids, by reducing TG and increasing HDL-C levels, in both diabetic and nondiabetic patients, as confirmed in VA-HIT (Veterans Affairs HDL Intervention Trial) or FIELD (Fenofibrate Intervention and Event Lowering in Diabetes Study).
10 However, it is difficult to explain why LDL-C increased again after 12 weeks of statin therapy in men with subclinical hyperlipemia. The most valid explanation would be medication non-adherence, although not confirmed by any of the patients.
In the present study postprandial lipemia was calculated as changes in TG levels, induced by a standard high-fat meal, compared to fasting triglyceridemia (∆TG = TG p -TG o ). Prior to hypolipemic therapy, the magnitude of changes in TG were more than twofold higher in DM patients compared to men with normolipemia or hyperlipemia and no DM. This finding indicates that abnormalities in TG homeostasis observed in diabetic patients, are likely caused by a number of factors, not only lipid disturbances. One men (it was also observed in the control group after the meal). Moreover, in patients with DM there was a correlation between postprandial levels of TG and hsCRP after 12 weeks. Contrary to the control group, there were no associations between fasting or postprandial HDL 3 -C and hsCRP levels in the DM and AH groups (TAbLE 4). The analysis of relationships between particular variables showed that normalization of lipid profiles did not completely restore all the associations between fasting lipid and protein para meters observed in controls.
dIsCussION In all diabetic men lipid levels were increased. Hypolipemic therapy reduced elevated lipid levels as expected. Statin administration led to a decrease in total cholesterol and LDL levels in men with DM and hypercholesterolemia. Such effect of statins has been convincingly demonstrated in randomized trials including UKPDS (United Kingdom Prospective Diabetes Study), CARE (Cholesterol and Recurrent Events), CARDS, 4S, HPS (Heart Protection Data are given as mean ± standard deviation. a significant differences compared to the control group (with normolipemia); p <0.001 b significant differences compared to baseline (before therapy) fasting or postprandial para meter levels; p <0.05 c significant differences compared to baseline fasting (before therapy) or postprandial para meter levels; p <0.01
Abbreviations: apo A - apolipoprotein A, apo B - apolipoprotein B, HDL-C - high-density lipoprotein cholesterol, hsCRP - high-sensitivity C-reactive protein, LDL-C - low-density lipoprotein cholesterol, TG - triglycerides prevents atherosclerosis. This mechanism seems to be impaired in diabetic patients. Hypolipemic therapy significantly reduced postprandial lipemia and restored desirable correlations between TG and HDL-C or TG and HDL 3 -C levels. Similarly to Taskinen et al., we observed a positive correlation between TG and apo B levels.
3
The authors suggested that the production of TG and apo B contained in type-1 and -2 VLDL in diabetic patients was associated with apo B overproduction and a decreased ability of insulin to suppress the synthesis of type-1 VLDL. In the present study, the correlation between TG and apo B in diabetic men was observed after 6 weeks of treatment, and in some patients postprandial apo B levels increased after 12 weeks. The correlation between TG and apo B also occurred in AH men during treatment and in the control group (after the meal), and was not restricted only to diabetic subjects.
Hypolipemic therapy did not restore all relationships between variables in patients with DM. Correlations between TG and hsCRP levels (positive) or between HDL 3 -C and hsCRP levels (inverse) did of the apparent factors is insulin deficiency or resistance, which reduces the activity of lipases hydrolyzing TG-rich lipoproteins and enhances liver fatty acid uptake. The present study also demonstrated abnormal associations between TG and HDL in diabetic patients, i.e. between TG and HDL 3 subfraction, evident in the absence of inverse linear relationships between TG and HDL-C, or TG and HDL 3 -C levels -correlations which were observed in normolipemic men and patients with hyperlipemia and no DM.
An inverse correlation between TG and HDL 3 -C levels is beneficial in terms of the mechanisms which protect from accelerated atherosclerosis. HDL significantly inhibits platelet activation through acetylhydrolase and reduces thrombocyte aggregation as glycoprotein IIb/IIIa inhibitor. Moreover, HDL stimulates protein C and S activation. Only HDL 2 can act as a cofactor of the active protein C. On the other hand, oxidized forms of HDL 3 have procoagulant properties by activating plasminogen activator inhibitor type 1.
5,11 Thus, a decrease in HDL 3 levels accompanied by an increase in TG levels in nondiabetic men can be viewed as a mechanism that Data are given as mean ± standard deviation. a significant differences compared to the control group with normolipemia; p <0.001 b significant differences compared to baseline (before therapy) fasting or postprandial para meter levels; p <0.05
Abbreviations: see TAbLE 2 study also demonstrated that the statin was less potent than the fibrate in men with DM. Of note, baseline TG levels in patients treated with statin or fibrate were below 400 mg/dl, thus the drug effect on postprandial lipemia was only slightly dependent on the fasting levels.
In conclusion, the results of our study confirmed that type 2 DM is associated with increased postprandial lipemia. One of the mechanisms behind this reaction could be disturbed inter actions between lipid variables (TG and cholesterol present in HDL 3 subfraction) or between lipid and inflammatory para meters (TG and hsCRP). Hypolipemic therapy resulted in reduced postprandial lipemia in patients with diabetes and restored correlations between the para meters.
Detection of lipid intolerance using a postprandial lipemia test allows to identify diabetic individuals who require hypolipemic treatment. Acceptable levels of postprandial lipemia cannot be determined for the general population because they depend on fasting lipemia, the type of lipid disorders, and comorbidities. not occur, although hsCRP levels decreased from a mean value of 2.1 mg/l to 1.6 mg/l.
The occurrence of the above correlations in the control group is likely to be the consequence of an inverse correlation between TG and HDL 3 -C levels. The correlations between TG or HDL-C and hsCRP are consistent with the hypothesis that TG has a pro-inflammatory activity while HDL has an anti-inflammatory activity.
11-13 Based on our study, it can be assumed that HDL 3 subfraction participates in an anti-inflammatory response. A postprandial inverse correlation between HDL 3 and hsCRP in normolipemic men is essential given the fact that hsCRP levels are unaltered following a meal. On the other hand, other investigators observed complement activation after a meal. 14, 15 Increased postprandial lipemia is believed to precede abnormal fasting lipemia. 16 The present study showed that high postprandial lipemia is associated with abnormal fasting lipemia in diabetic men, and is significantly reduced by hypolipemic therapy. In diabetic patients with fasting TG levels 150-400 mg/dl, statin administration was less effective than fibrate in reducing the postprandial increases in TG-rich lipoprotein levels. 17 The current TAbLE Correlations between lipid (lipid and protein) levels measured at baseline, after 6 and 12 weeks of therapy in men with type 2 diabetes (DM), men with hyperlipemia and no diabetes (asymptomatic hyperlipemia - AH) and control subjects Correlations between para meters At baseline After 6 weeks After 12 weeks 0 P 0 P 0 P DM (n = 26) Abbreviations: P - postprandial, NS - nonsignificant, 0 - fasting, others - see TAbLE 2 
